Studybox Research Dual Submission Studies
Bacterial Vaginosis Point-of-Care Test
One integrated study supporting both 510(k) clearance and CLIA waiver.
Studybox
Dual Submission Studies
Bacterial vaginosis is the most common cause of vaginal discharge in reproductive-age women, and its reference standards are old: the Amsel clinical criteria at the bedside and the Nugent Gram-stain score in the laboratory. Neither is perfect, the Nugent score includes an intermediate category, and point-of-care tests have been compared to one or both with pre-specified rules for intermediates. The clinical study enrolls symptomatic women, collects the device swab alongside a smear for Nugent scoring and the Amsel components, and reports performance against the chosen reference.
Because the reference depends on trained microscopy readers, central reading of Gram stains with documented inter-reader agreement is a standard element, and Amsel documentation at the visit has to be standardized across sites that may not routinely perform pH or whiff testing. Intended use is typically restricted to symptomatic women, since asymptomatic BV has uncertain clinical significance and the reference performs differently in that population.
- Analyte
- Markers of bacterial vaginosis: sialidase enzyme activity, vaginal pH and amines, or nucleic acid of BV-associated bacteria, depending on the device
- Therapeutic area
- Women's Health
- Specimens
- Vaginal Swab
- Intended-use settings
- physician office, urgent care, emergency department
- Operators
- Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.
- Comparator
- Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.
Dual Submission specifics
What Changes for This Assay on This Pathway.
- A single prospective study of symptomatic women at waived sites, with the device run by untrained operators and Gram stain smears read centrally, supports both components.
- Amsel components recorded at waived sites by clinic staff are a secondary reference, and their consistency across sites should be monitored.
- Molecular BV devices on a point-of-care instrument follow the same reference design but with instrument-oriented flex studies rather than visual-read stress tests.
Endpoints the study must support
- Sensitivity and specificity against Nugent score (and against Amsel criteria where pre-specified), with 95% confidence intervals, in symptomatic women
- Transparent handling of intermediate Nugent scores, with analyses excluding and including them
- Agreement between self-collected and clinician-collected swabs where both are claimed, and invalid rate in waived settings
Enrollment realities
Driven by Nugent-positive symptomatic women, who are a substantial share of women presenting with discharge, so accrual is faster than for most STI tests; intermediate Nugent results and inadequate smears are predictable losses.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run dual submission studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
Bacterial Vaginosis Point-of-Care Test Study Questions.
01 Who operates the bacterial vaginosis point-of-care test in a dual submission study?
Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.
02 What is the comparator for a bacterial vaginosis point-of-care test study?
Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.
03 What drives enrollment for a bacterial vaginosis point-of-care test study?
Driven by Nugent-positive symptomatic women, who are a substantial share of women presenting with discharge, so accrual is faster than for most STI tests; intermediate Nugent results and inadequate smears are predictable losses.
Let's talk IVD research
Planning a bacterial vaginosis point-of-care test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the dual submission pathway.